Method for Treating Neurodegenerative Diseases with Polymer-Flavonoid Conjugates
Summary
The USPTO published patent application US20260097130A1 for a method of treating neurodegenerative diseases using polymer-flavonoid conjugates. Inventors Chun-Ting Cheng, Kuo-Liang Hou, and Pauline Ying Lau claim compositions that enable therapeutic materials to cross the blood-brain barrier. The application covers treatment of Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease using the disclosed nanocomplex formulations.
What changed
The USPTO published a patent application disclosing methods for treating neurodegenerative diseases using polymer-flavonoid conjugates and nanocomplex compositions. The invention enables therapeutic materials to cross the blood-brain barrier through administration of the claimed conjugates, targeting Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease. The application covers both the conjugate compositions and methods of administering them to subjects in need of treatment.
For pharmaceutical and biotechnology companies developing CNS therapeutics, this patent represents potential prior art that could affect Freedom to Operate analyses for similar delivery technologies. Companies working on blood-brain barrier penetration technologies or flavonoid-based therapeutics should evaluate whether their development activities fall within the scope of the claimed invention.
What to do next
- Monitor for patent grant or office action
- Review claims for Freedom to Operate analysis
- Evaluate licensing opportunities if developing similar therapeutics
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD FOR TREATING NEURODEGENERATIVE DISEASES
Application US20260097130A1 Kind: A1 Apr 09, 2026
Inventors
Chun-Ting Cheng, Kuo-Liang Hou, Pauline Ying Lau
Abstract
The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.
CPC Classifications
A61K 47/6849 A61K 9/5123 A61K 9/5146 A61K 31/353 A61K 47/6803 A61K 47/6935 C07K 16/2803 C07K 16/2809
Filing Date
2025-12-02
Application No.
19406217
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.